PYC Therapeutics (PYC.AX) Stock Price

PYC Therapeutics Price

ASX·CLOSED
2.04AUD-0.10 (-4.55 %)
Market closed

Over the last 19 years PYC Therapeutics grew revenue by 23.3% annually, reaching 26.17 M AUD. For PYC Therapeutics, the net margin of -192.2% is up versus -558.2% a few years ago. The consensus 12-month price target for PYC Therapeutics is 3.96 AUD, about 94.0% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 140% above its 52-week low.

PYC Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of PYC Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how PYC Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing PYC Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

PYC Therapeutics Stock Price History
DatePYC Therapeutics Price
8/7/20262.04 AUD
8/6/20262.13 AUD
8/5/20262.10 AUD
8/4/20262.00 AUD
8/3/20261.85 AUD
7/31/20261.70 AUD
7/30/20261.67 AUD
7/29/20261.63 AUD
7/28/20261.63 AUD
7/27/20261.65 AUD
7/24/20261.66 AUD
7/23/20261.67 AUD
7/22/20261.61 AUD
7/21/20261.63 AUD
7/20/20261.59 AUD
7/17/20261.61 AUD
7/16/20261.67 AUD
7/15/20261.61 AUD
7/14/20261.54 AUD
7/13/20261.54 AUD
7/10/20261.55 AUD
7/9/20261.52 AUD
7/8/20261.56 AUD
7/7/20261.53 AUD
7/6/20261.55 AUD
7/3/20261.55 AUD
7/2/20261.63 AUD
7/1/20261.71 AUD
6/30/20261.68 AUD
6/29/20261.63 AUD
6/26/20261.52 AUD
6/25/20261.53 AUD
6/24/20261.51 AUD
6/23/20261.56 AUD
6/22/20261.52 AUD
6/19/20261.54 AUD
6/18/20261.43 AUD
6/17/20261.29 AUD
6/16/20261.26 AUD
6/15/20261.23 AUD
6/12/20261.21 AUD
6/11/20261.16 AUD
6/10/20261.16 AUD
6/9/20261.20 AUD
6/5/20261.24 AUD
6/4/20261.27 AUD
6/3/20261.27 AUD
6/2/20261.32 AUD
6/1/20261.33 AUD
5/29/20261.39 AUD
5/28/20261.39 AUD
5/27/20261.40 AUD
5/26/20261.36 AUD
5/25/20261.35 AUD
5/22/20261.36 AUD
5/21/20261.33 AUD
5/20/20261.29 AUD
5/19/20261.32 AUD
5/18/20261.33 AUD
5/15/20261.43 AUD
5/14/20261.45 AUD
5/13/20261.44 AUD
5/12/20261.34 AUD
5/11/20261.26 AUD
5/8/20261.23 AUD
5/7/20261.18 AUD
5/6/20261.16 AUD
5/5/20261.17 AUD
5/4/20261.21 AUD
5/1/20261.23 AUD
4/30/20261.26 AUD
4/29/20261.32 AUD
4/28/20261.30 AUD
4/27/20261.31 AUD
4/24/20261.29 AUD
4/23/20261.29 AUD
4/22/20261.28 AUD
4/21/20261.30 AUD
4/20/20261.30 AUD
4/17/20261.28 AUD
4/16/20261.23 AUD
4/15/20261.21 AUD
4/14/20261.15 AUD
4/13/20261.14 AUD
4/10/20261.17 AUD
4/9/20261.12 AUD
4/8/20261.16 AUD
4/7/20261.07 AUD
4/2/20261.12 AUD
4/1/20261.16 AUD
3/31/20261.10 AUD
3/30/20261.12 AUD
3/27/20261.10 AUD
3/26/20261.17 AUD
3/25/20261.22 AUD
3/24/20261.18 AUD
3/23/20261.20 AUD
3/20/20261.33 AUD
3/19/20261.37 AUD
3/18/20261.39 AUD
3/17/20261.37 AUD
3/16/20261.40 AUD
3/13/20261.41 AUD
3/12/20261.46 AUD
3/11/20261.50 AUD
3/10/20261.47 AUD
3/9/20261.48 AUD
3/6/20261.50 AUD
3/5/20261.49 AUD
3/4/20261.47 AUD
3/3/20261.49 AUD
3/2/20261.50 AUD
2/27/20261.50 AUD
2/26/20261.50 AUD
2/25/20261.50 AUD
2/24/20261.49 AUD
2/23/20261.50 AUD
2/20/20261.50 AUD
2/19/20261.49 AUD
2/18/20261.50 AUD
2/17/20261.49 AUD
2/16/20261.50 AUD
2/13/20261.51 AUD
2/12/20261.48 AUD
2/11/20261.50 AUD
2/10/20261.48 AUD
2/9/20261.50 AUD
2/6/20261.50 AUD
2/5/20261.50 AUD
2/4/20261.51 AUD
1/30/20261.60 AUD
1/29/20261.62 AUD
1/28/20261.66 AUD
1/27/20261.66 AUD
1/23/20261.68 AUD
1/22/20261.66 AUD
1/21/20261.71 AUD
1/20/20261.68 AUD
1/19/20261.69 AUD
1/16/20261.74 AUD
1/15/20261.71 AUD
1/14/20261.65 AUD
1/13/20261.63 AUD
1/12/20261.64 AUD
1/9/20261.68 AUD
1/8/20261.70 AUD
1/7/20261.68 AUD
1/6/20261.67 AUD
1/5/20261.68 AUD
1/2/20261.65 AUD
12/31/20251.65 AUD
12/30/20251.64 AUD
12/29/20251.71 AUD
12/24/20251.70 AUD
12/23/20251.56 AUD
12/22/20251.51 AUD
12/19/20251.50 AUD
12/18/20251.49 AUD
12/17/20251.45 AUD
12/16/20251.49 AUD
12/15/20251.47 AUD
12/12/20251.47 AUD
12/11/20251.52 AUD
12/10/20251.53 AUD
12/9/20251.49 AUD
12/8/20251.51 AUD
12/5/20251.49 AUD
12/4/20251.50 AUD
12/3/20251.47 AUD
12/2/20251.53 AUD
12/1/20251.47 AUD
11/28/20251.60 AUD
11/27/20251.53 AUD
11/26/20251.49 AUD
11/25/20251.47 AUD
11/24/20251.40 AUD
11/21/20251.38 AUD
11/20/20251.38 AUD
11/19/20251.37 AUD
11/18/20251.26 AUD
11/17/20251.30 AUD
11/14/20251.37 AUD
11/13/20251.32 AUD
11/12/20251.19 AUD
11/11/20251.18 AUD
11/10/20251.18 AUD
11/7/20251.16 AUD
11/6/20251.16 AUD
11/5/20251.16 AUD
11/4/20251.18 AUD
11/3/20251.22 AUD
10/31/20251.26 AUD
10/30/20251.18 AUD
10/29/20251.20 AUD
10/28/20251.20 AUD
10/27/20251.22 AUD
10/24/20251.20 AUD
10/23/20251.22 AUD
10/22/20251.25 AUD
10/21/20251.24 AUD
10/20/20251.22 AUD
10/17/20251.20 AUD
10/16/20251.28 AUD
10/15/20251.22 AUD
10/14/20251.15 AUD
10/13/20251.12 AUD
10/10/20251.15 AUD
10/9/20251.17 AUD
10/8/20251.21 AUD
10/7/20251.22 AUD
10/6/20251.13 AUD
10/3/20251.14 AUD
10/2/20251.10 AUD
10/1/20251.07 AUD
9/30/20251.02 AUD
9/29/20251.03 AUD
9/26/20250.99 AUD
9/25/20251.00 AUD
9/24/20251.02 AUD
9/23/20251.02 AUD
9/22/20251.04 AUD
9/18/20250.89 AUD
9/17/20250.85 AUD
9/16/20251.22 AUD
9/15/20251.22 AUD
9/12/20251.22 AUD
9/11/20251.22 AUD
9/10/20251.22 AUD
9/9/20251.24 AUD
9/8/20251.26 AUD
9/5/20251.25 AUD
9/4/20251.27 AUD
9/3/20251.25 AUD
9/2/20251.27 AUD
9/1/20251.24 AUD
8/29/20251.28 AUD
8/28/20251.29 AUD
8/27/20251.29 AUD
8/26/20251.30 AUD
8/25/20251.30 AUD
8/22/20251.30 AUD
8/21/20251.32 AUD
8/20/20251.27 AUD
8/19/20251.32 AUD
8/18/20251.32 AUD
8/15/20251.32 AUD
8/14/20251.26 AUD
8/13/20251.35 AUD
8/12/20251.34 AUD
8/11/20251.26 AUD
Access this data via the Eulerpool API
Get Free API Key

PYC Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
16.07 M AUD
-14.26 M AUD
-13.86 M AUD
Jan 1, 2023
15.89 M AUD
-23.28 M AUD
-22.79 M AUD
Jan 1, 2024
22.86 M AUD
-37.57 M AUD
-37.73 M AUD
Jan 1, 2025
26.17 M AUD
-49.75 M AUD
-50.30 M AUD
Jan 1, 2026 (e)
5.05 M AUD
-76.43 M AUD
-68.79 M AUD
Jan 1, 2027 (e)
17.68 M AUD
-127.54 M AUD
-61.41 M AUD
Jan 1, 2028 (e)
120.42 M AUD
-150.85 M AUD
135.77 M AUD
Jan 1, 2029 (e)
53.13 M AUD
-99.76 M AUD
-20.70 M AUD

PYC Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 8:18 PM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEk AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESB
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
–––2.00––2.003.0016.0015.0022.0026.005.0017.00120.0053.00
–––––––50.00433.33-6.2546.6718.18-80.77240.00605.88-55.83
–––50.00––-50.00-33.33-6.25-6.67-4.55-3.85-20.00-5.88-0.83-1.89
-1,000.00-1,000.00-1,000.001,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00
-5.00-5.00-6.00-4.00-9.00-7.00-7.00-18.00-14.00-23.00-37.00-49.00-76.00-127.00-150.00-99.00
–––-200.00––-350.00-600.00-87.50-153.33-168.18-188.46-1,520.00-747.06-125.00-186.79
-3.00-2.00-3.00-1.00-7.00-4.00-6.00-17.00-13.00-22.00-37.00-50.00-68.00-61.00135.00-20.00
–-33.3350.00-66.67600.00-42.8650.00183.33-23.5369.2368.1835.1436.00-10.29-321.31-114.81
0.951.231.932.062.202.412.753.090.320.330.410.510.510.510.510.51
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales PYC Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue PYC Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare PYC Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares PYC Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against PYC Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

PYC Therapeutics stock margins

The PYC Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PYC Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PYC Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-612,400.00 %
-585.94 %
-558.22 %
Jan 1, 2022
-612,400.00 %
-88.76 %
-86.28 %
Jan 1, 2023
-612,400.00 %
-146.49 %
-143.43 %
Jan 1, 2024
-612,400.00 %
-164.37 %
-165.06 %
Jan 1, 2025
-612,400.00 %
-190.08 %
-192.21 %
Jan 1, 2026 (e)
-612,400.00 %
-1,513.50 %
-1,362.21 %
Jan 1, 2027 (e)
-612,400.00 %
-721.61 %
-347.41 %
Jan 1, 2028 (e)
-612,400.00 %
-125.27 %
112.75 %

PYC Therapeutics Stock Revenue, EBIT, Earnings per Share

The PYC Therapeutics earnings per share therefore indicates how much revenue PYC Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2022
0.05 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2023
0.05 AUD
-0.07 AUD
-0.07 AUD
Jan 1, 2024
0.06 AUD
-0.09 AUD
-0.09 AUD
Jan 1, 2025
0.05 AUD
-0.10 AUD
-0.10 AUD
Jan 1, 2026 (e)
0.01 AUD
-0.15 AUD
-0.13 AUD
Jan 1, 2027 (e)
0.03 AUD
-0.25 AUD
-0.12 AUD
Jan 1, 2028 (e)
0.23 AUD
-0.29 AUD
0.26 AUD

PYC Therapeutics business model & stock analysis

PYC Therapeutics Ltd is a biopharmaceutical company based in Sydney, Australia. The company was founded in 2017 by experienced pharmaceutical and biotech managers and currently employs over 40 employees. The history of PYC Therapeutics began with the development of a novel therapy platform called "PCytTM", which is based on the use of artificial proteins. These proteins can enhance the uptake of drugs into cells, thereby increasing the effectiveness of various medications. In 2018, PYC Therapeutics achieved a significant milestone by being included in the prestigious Accelerating Commercialisation program of the Australian government. PYC Therapeutics' business model focuses on the research and development of innovative cancer therapies and rare genetic diseases. The company strives to focus on diseases for which there is currently no effective treatment. This is intended to be achieved through partnerships, licensing, and potentially through the acquisition of companies and technologies. PYC Therapeutics shapes its processes through collaboration with experts in the fields of medicine, pharmacy, biotechnology, and chemistry. The divisions of PYC Therapeutics can be divided into the following areas of activity: drug development, platform technology, partnerships, and research and development. Under drug development, PYC Therapeutics understands the actual production of new cancer therapeutics and medications for the treatment of rare genetic diseases. The company relies on its internal research and also utilizes in-licensed technologies and acquisitions to develop novel drugs. Platform technology is a key success factor for PYC Therapeutics. The company has developed a highly effective method with PCytTM to optimize drug transport. This can significantly enhance the efficacy of medications. This technology has the potential to revolutionize the treatment of many diseases. Partnerships are an important part of PYC Therapeutics' business model. The company focuses on long-term collaborations with large pharmaceutical and biotech companies. This cooperation is intended to accelerate the development, approval, and commercialization of new medications. Research and development form the core of PYC Therapeutics' business model. The company invests significantly in the exploration of new therapeutics for cancer and rare genetic diseases. Since its inception, the company has continuously expanded its development platform and has become a key player in the industry. One of PYC Therapeutics' most important pipeline products is "PYC-06". PYC-06 is a medication developed for the treatment of acute myeloid leukemia (AML). The therapy aims to enhance the potential of chemotherapeutics by using PCytTM. The initial results of clinical studies show very promising results. Overall, PYC Therapeutics is an important player in the field of innovative cancer care and the treatment of rare genetic diseases. The company has a strong pipeline of novel therapeutics based on its PCytTM technology. PYC Therapeutics strives to improve the treatment of cancer and rare diseases and achieve a better quality of life for patients. The business model of PYC Therapeutics focuses on partnerships, innovative developments, and scientific research that contribute to advancing the industry.

PYC Therapeutics SWOT Analysis

Strengths

  • PYC Therapeutics possesses a strong and experienced management team with a track record of success.
  • The company has a diverse pipeline of innovative therapeutics, targeting various diseases, which provides opportunities for growth and revenue diversification.
  • PYC Therapeutics has established strategic partnerships with reputable organizations, allowing access to resources, expertise, and potential market expansion.

Weaknesses

  • As a relatively young biotech company, PYC Therapeutics may face challenges in terms of limited financial resources, potentially impacting research and development efforts.
  • The success of PYC Therapeutics heavily relies on the development and commercialization of its pipeline products. Any setbacks or failures in clinical trials could have a significant impact on the company's growth prospects.
  • PYC Therapeutics operates in a highly competitive industry, which may intensify market competition and increase barriers to market entry for its products.

Opportunities

  • The increasing global prevalence of various diseases presents significant opportunities for PYC Therapeutics to address unmet medical needs and gain market share.
  • Advancements in technology and scientific research open doors for PYC Therapeutics to explore novel therapeutic approaches, potentially leading to the development of breakthrough treatments.
  • Strategic collaborations and partnerships offer potential for business expansion, market access, and enhanced product development capabilities.

Threats

  • Regulatory challenges and compliance requirements in the biotech and pharmaceutical industry may pose potential roadblocks for PYC Therapeutics in achieving timely product approvals and market entry.
  • Intellectual property risks and the possibility of patent disputes can jeopardize PYC Therapeutics' ability to protect and commercialize its innovations.
  • Economic downturns or changing healthcare policies can impact market dynamics and funding availability, potentially affecting PYC Therapeutics' operations and financial stability.

PYC Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

PYC Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

PYC Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

PYC Therapeutics shares outstanding

The number of shares of PYC Therapeutics was 512.5 M in 2025. This indicates how many shares PYC Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
3.09 B Stocks
Jan 1, 2022
323.64 M Stocks
Jan 1, 2023
334.48 M Stocks
Jan 1, 2024
410.05 M Stocks
Jan 1, 2025
512.50 M Stocks
Jan 1, 2026 (e)
512.50 M Stocks
Jan 1, 2027 (e)
512.50 M Stocks
Jan 1, 2028 (e)
512.50 M Stocks

PYC Therapeutics stock splits

In PYC Therapeutics's history, there have been no stock splits.

Current PYC Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
3.96
Last Price
2.04
Currency
AUD
12M Return Potential
94.00 %
LTM Return
0 %

PYC Therapeutics shareholder structure

% Name
36.43484%
Tribe (Alan William)
Tribe (Alan William)
16.36114%
RA Capital Management, LP
RA Capital Management, LP
5.75487%
Firetrail Investments Pty Limited
Firetrail Investments Pty Limited
5.33929%
McCusker Holdings Pty. Ltd.
McCusker Holdings Pty. Ltd.
0.81952%
Mccusker Foundation Ltd
Mccusker Foundation Ltd
0.46769%
FIL Investment Management (Hong Kong) Limited
FIL Investment Management (Hong Kong) Limited

PYC Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
35.7%
Float Shares
-
Shares Outstanding
-

PYC Therapeutics Executives and Management Board

7 members · avg. age 53 · 0 % women

RH

Dr. Rohan Hockings

Chief Executive Officer, Executive Director · since 2016

417,503.00 AUD

Management

AT

Mr. Andrew Taylor

Chief Financial Officer, Joint Company Secretary

–
GN

Dr. Glenn Noronha

Chief Development Officer

–
KH

Mr. Kevin Hart

Joint Company Secretary

–

Board of Directors

MR

Dr. Michael Rosenblatt

Non-Executive Independent Director

111,291.00 AUD
JH

Mr. Jason Haddock (53)

Non-Executive Independent Director

109,334.00 AUD
AT

Mr. Alan Tribe

Non-Executive Chairman of the Board

70,000.00 AUD

PYC Therapeutics Supply Chain

Frequently asked questions about PYC Therapeutics

The business model of PYC Therapeutics Ltd is focused on the discovery and development of novel RNA-targeted therapies to address genetic diseases caused by RNA gain-of-function. By utilizing their proprietary platform called RNA PROTEIN BINDING MOTIFS (RBMs), PYC Therapeutics aims to unlock the potential of RNA therapeutics and provide innovative solutions for patients with unmet medical needs. With their specialized expertise in RNA biology and drug discovery, PYC Therapeutics is dedicated to advancing their pipeline of RNA-targeted therapies and making a meaningful impact in the field of precision medicine.

PYC Therapeutics Ltd is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of PYC Therapeutics Ltd in the market are other companies involved in the field of gene therapy and genetic diseases, such as Sarepta Therapeutics, Solid Biosciences, and Spark Therapeutics.

PYC Therapeutics Ltd is an innovative biotechnology company based in Australia. Established in 1996, the company has a rich history in developing novel therapeutics for genetic diseases. With a strong focus on precision medicine, PYC Therapeutics utilizes its proprietary platform, known as aRNA, to develop RNA-based therapies that target specific genes and restore their normal function. The company has gained recognition for its groundbreaking research and collaborations with leading academic and healthcare institutions. As a result, PYC Therapeutics is well-poised to address the unmet medical needs of patients with genetic disorders and drive advancements in the field of precision medicine.

PYC Therapeutics Ltd has achieved several significant milestones. The company successfully completed its initial public offering in August 2020, raising substantial funds to support its research and development efforts. Additionally, PYC Therapeutics has made remarkable progress in advancing its proprietary RNA splicing platform, which holds tremendous potential in treating genetic diseases. The company has also secured strategic partnerships and collaborations with renowned academic institutions and pharmaceutical companies, further validating the potential of its innovative technologies. PYC Therapeutics continues to actively pursue groundbreaking research and development activities, solidifying its position as a leading player in the field of genetic medicine.

PYC Therapeutics Ltd is primarily present in Australia.

PYC Therapeutics Ltd is a biotechnology company that focuses on developing transformative RNA therapeutics to treat a range of genetic diseases. The company is committed to delivering innovative solutions aimed at improving patients' lives and addressing unmet medical needs. PYC Therapeutics is guided by a strong corporate philosophy centered around scientific excellence, collaboration, and integrity. By leveraging cutting-edge RNA technologies and a deep understanding of disease biology, PYC Therapeutics aims to advance groundbreaking therapies and make a significant impact in the field of genetic medicine.

Analysts currently set an average price target of 3.63 AUD for the PYC Therapeutics stock (median: 3.96 AUD), implying +77.8 % versus the latest price. The consensus is based on 9 analyst ratings.

PYC Therapeutics Analyst Price Targets 2026

9 analysts currently rate the PYC Therapeutics stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect PYC Therapeutics to generate revenue of 5.05 M AUD and earnings per share of -0.13 AUD.

PYC Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the PYC Therapeutics share trades at 1.25 EUR (2.04 AUD).

The PYC Therapeutics share (PYC.AX) is listed on 2 stock exchanges, including: Frankfurt (PH7.F), ASX (PYC.AX).

PYC Therapeutics Ltd is a pharmaceutical company specializing in the development and commercialization of therapeutic solutions for rare genetic diseases. The company is headquartered in Australia and has branches in the USA and UK. PYC Therapeutics focuses on diseases caused by mutations in the RNA splicing process. The business model of PYC Therapeutics is based on the development of new generations of RNA splicing modulators that enable correct RNA splicing. RNA splicing modulation aims to develop novel therapeutic approaches to combat previously incurable rare diseases. The company uses newly gained molecular insights to develop targeted therapeutic approaches. An important division of PYC Therapeutics is nucleic acid-based therapeutics targeting mRNA modulation. The products in this division aim to correct "mis-spliced" mRNA and allow for the production of healthy proteins. One outstanding product of PYC Therapeutics is the RNA splicing modulation therapy PYC46. This therapy aims to produce a protein that prevents the entry of viruses into cells by correcting mis-spliced RNA. What makes PYC46 special is that this therapy can have broad applications in fighting various viruses. The company has also formed a partnership with the American company Ultragenyx Pharmaceutical Inc. to jointly advance the development of RNA splicing modulators. Ultragenyx Pharmaceutical Inc. is a renowned biotech company specializing in rare diseases. The partnership allows both companies to leverage synergies to drive the development of new and effective therapeutics. PYC Therapeutics aims to develop a variety of new therapeutic approaches for the treatment of rare genetic diseases and make them accessible to the millions of people affected by these rare diseases. The company relies on close collaboration with academic institutions and research facilities in the industry to advance its research and development initiatives. Overall, PYC Therapeutics places great importance on well-founded and sustainable research and development. Only on this basis can the company develop innovative solutions and products to provide high benefits to patients worldwide.

The expected revenue of PYC Therapeutics is 5.05 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of PYC Therapeutics is -68.79 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PYC Therapeutics is currently -15.20. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PYC Therapeutics stock.

The price-to-sales ratio (P/S) of PYC Therapeutics is currently 207.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PYC Therapeutics stock.

The Eulerpool Quality Score for PYC Therapeutics is 4/10.

The ISIN of PYC Therapeutics is AU000000PYC7. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of PYC Therapeutics is A0D8ZY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of PYC Therapeutics is PYC.AX. The ticker symbol is used to trade PYC Therapeutics shares on the stock exchange.

PYC Therapeutics paid dividends every year for the past 0 years.

PYC Therapeutics is assigned to the 'Health' sector.

The dividends of PYC Therapeutics are distributed in AUD.

All fundamentals and in-depth analysis of PYC Therapeutics

Our stock analysis for PYC Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PYC Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

PYC Therapeutics Stock
PYC Therapeutics Revenue→
PYC Therapeutics Stock
PYC Therapeutics Net Income→
PYC Therapeutics Stock
PYC Therapeutics P/E→
PYC Therapeutics Stock
PYC Therapeutics P/S→
PYC Therapeutics Stock
PYC Therapeutics EBIT→
PYC Therapeutics Stock
PYC Therapeutics Dividend→
PYC Therapeutics Stock
PYC Therapeutics Directors Dealings→
PYC Therapeutics Stock
PYC Therapeutics Stocks→
PYC Therapeutics Stock
PYC Therapeutics Market capitalization→
PYC Therapeutics Stock
PYC Therapeutics Debt→
PYC Therapeutics Stock
PYC Therapeutics Liabilities→
PYC Therapeutics Stock
PYC Therapeutics Equity→
PYC Therapeutics Stock
PYC Therapeutics AAQS→
PYC Therapeutics Stock
PYC Therapeutics Employees→
PYC Therapeutics Stock
PYC Therapeutics ROE→
PYC Therapeutics Stock
PYC Therapeutics ROA→
PYC Therapeutics Stock
PYC Therapeutics ROCE→
PYC Therapeutics Stock
PYC Therapeutics News→
PYC Therapeutics Stock
PYC Therapeutics Analyst Price Targets→

Health Stocks

Pyridam Farma Tbk PTPW Medtech GroupPyxis OncologyPuriblood Medical CoPZ CormayPure BiologicsPZ Wind DownPuraPharm CorpQ & M Dental Group (Singapore)Puma BiotechnologyQ lineaPulsenmoreAll Stocks A–Z →